Fretz Marjan, Jin Jing, Conibere Robin, Penning Neal A, Al-Taei Saly, Storm Gert, Futaki Shiroh, Takeuchi Toshihide, Nakase Ikuhiko, Jones Arwyn T
Welsh School of Pharmacy, Redwood Building, Cardiff University, Cardiff, CF10 3XF, Wales, UK.
J Control Release. 2006 Nov 28;116(2):247-54. doi: 10.1016/j.jconrel.2006.07.009. Epub 2006 Jul 14.
Protein transduction domains such as those derived from the HIV protein TAT have great potential as vectors for delivery of therapeutic entities such as genes and proteins into cells. Extensive studies have shown that a major fraction of the most studied variants enters cells via an endocytic mechanism. However, controversy surrounds the exact uptake mechanism and whether a specific pathway is utilised. Studies showing inhibition of uptake of protein transduction domains in the presence of ion-transport inhibitors such as amiloride and its more potent analogue 5-(N-ethyl-N-isopropyl) amiloride (EIPA) suggest a link between peptide internalisation and macropinocytosis. In this study, using immunolabelling of early and late components of the endocytic pathway, we show that treatment of cells with EIPA and to a lesser extent amiloride affects the morphology and subcellular location of early, late endosomes and lysosomes. Enlarged early and late endocytic structures were observed in EIPA-treated cells, and these organelles accumulated in a perinuclear region. Results from experiments investigating the effects of EIPA on distribution of fluorescent octaarginine were in agreement with the immunolocalisation studies. Treatment of the CD34(+) leukaemia cell line KG1a with EIPA in the presence of fluorescent conjugates of HIV-TAT peptide and octaarginine showed distinct vesicular staining in agreement with untreated cells but EIPA-treated cells were additionally characterized by increased localization of the peptides in the cytosol. At levels previously shown to inhibit uptake of HIV-TAT peptide and octaarginine in other cell lines, EIPA was without major effect on uptake of both peptides in KG1a cells.
诸如源自HIV蛋白TAT的蛋白质转导结构域,作为将基因和蛋白质等治疗实体递送至细胞的载体具有巨大潜力。广泛研究表明,大多数被研究变体的主要部分通过内吞机制进入细胞。然而,关于确切的摄取机制以及是否利用特定途径仍存在争议。有研究表明,在存在离子转运抑制剂如氨氯吡咪及其更强效类似物5-(N-乙基-N-异丙基)氨氯吡咪(EIPA)的情况下,蛋白质转导结构域的摄取受到抑制,这表明肽内化与巨胞饮作用之间存在联系。在本研究中,通过对内吞途径早期和晚期成分进行免疫标记,我们发现用EIPA处理细胞,以及在较小程度上用氨氯吡咪处理,会影响早期、晚期内体和溶酶体的形态及亚细胞定位。在EIPA处理的细胞中观察到早期和晚期内吞结构增大,并且这些细胞器聚集在核周区域。研究EIPA对荧光八聚精氨酸分布影响的实验结果与免疫定位研究一致。在HIV-TAT肽和八聚精氨酸的荧光偶联物存在下,用EIPA处理CD34(+)白血病细胞系KG1a,与未处理细胞一样显示出明显的囊泡染色,但EIPA处理的细胞的额外特征是肽在细胞质中的定位增加。在先前显示可抑制其他细胞系中HIV-TAT肽和八聚精氨酸摄取的水平下,EIPA对KG1a细胞中这两种肽的摄取没有主要影响。